Primed for resistance

David B. Solit () and Pasi A. Jänne ()
Additional contact information
David B. Solit: Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Pasi A. Jänne: Pasi A. Jänne is at the Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA.

Nature, 2012, vol. 483, issue 7387, 44-45

Abstract: A drug for treating melanoma is ineffective in colorectal cancers that have the same causative mutation. Studies of how cells adapt to the drug reveal why this is so, and suggest combination therapies that may be more effective. See Letter p.100

Date: 2012
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/483044a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:483:y:2012:i:7387:d:10.1038_483044a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/483044a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().